Predictive autoimmunity using autoantibodies: screening for anti-nuclear antibodies
Identificadores
URI: http://hdl.handle.net/20.500.12020/1293ISSN: 1434-6621
DOI: https://doi.org/10.1515/cclm-2017-0241
Autor/es
Perez, Dolores; Gilburd, B; cabrera-marante, Oscar; Serrano, Manuel; Naranjo, Laura; [et al.]Fecha
2018Tipo de documento
articleÁrea/s de conocimiento
Ciencias BiomédicasResumen
Background: Early detection of antinuclear antibodies
(ANA) in asymptomatic subjects is useful to predict autoimmune
diseases years before diagnosis. ANA have been
determined by indirect immunofluorescence (IIF) using
human epithelial type 2 (HEp-2) cells, which is considered
the gold standard technique. Multiplex technology
(BioPlex ANA Screen) has been introduced for ANA evaluation
in recent years. Nevertheless, concordance between
BioPlex and IIF is low and there is no harmonization
between both methods for detection of autoantibodies.
This study has aimed to clarify the clinical significance of
autoantibodies detected by BioPlex ANA Screen in subjects
with undiagnosed clinical suspicion of autoimmune
disease and to determine the predictive value of autoantibodies
detected by BioPlex ANA Screen.
Methods: A 3-year follow-up study was performed of
411 subjects without a clear diagnosis of autoimmune diseases
in whom autoantibodies were detected by BioPlex
ANA Screen that were negative by IIF on HEp-2 cells.
Results: At 3 years of follow-up, 312 (76%) subjects were
positive for autoantibodies by IIF and 99 subjects continued
to be negative. A diagnosis of autoimmune disease
was found in most of the subjects (87%).
Conclusions: BioPlex ANA Screen has greater sensitivity
than IIF on HEp-2 cells for autoantibodies detection. Early
detection of these antibodies by BioPlex can predict possible
development of autoimmune diseases.
Keywords: BioPlex ANA Screen; high sensitivity; indirect
immunofluorescence; positive predictive value; predictive
autoantibodies; systemic autoimmune rheumatic
diseases.